Drug class
Humanised monoclonal antibody; dual interleukin-17A and interleukin-17F inhibitor
Mechanism of action
Selectively binds and neutralises IL-17A and IL-17F, preventing their interaction with the IL-17 receptor complex and reducing downstream inflammatory signalling.
General use cases
- Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
- Treatment of active psoriatic arthritis in adults
- Treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation and active ankylosing spondylitis in adults; exact eligibility and indications are product- and jurisdiction-specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
